Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Grwth 3 Regulatory News (MIG3)

Share Price Information for Maven Grwth 3 (MIG3)

Share Price is delayed by 15 minutes
Get Live Data
42.40    0.00 (0.00%)
Bid:
41.40
Ask:
43.40
Spread: 2.00 (4.831%)
Market Cap: £65.92m
MIG3 Live PriceLast checked at - London Stock Exchange

Intraday Maven Grwth 3 Share Chart

Statement re Offer for Subscription

31 Jan 2022 16:25

RNS Number : 2039A
Maven Income and Growth VCT 3 PLC
31 January 2022
 

Maven Income and Growth VCT 3 PLC (the Company)

 

Offer for Subscription

 

31 January 2022

 

On 20 September 2021, the Company and Maven Income and Growth VCT 4 PLC (the "Companies") announced the publication of a joint Prospectus (comprising a Securities Note, Registration Document and Summary) in relation to offers for subscription of new Ordinary Shares of 10p each (together the "Offers" and each an "Offer").

 

The Board of the Company is pleased to advise that, with valid subscriptions received to date under the Company's Offer now approaching its initial fundraising target of £10 million, and in view of continued interest from potential investors, the Directors have resolved to utilise the over-allotment facility, as provided for under the terms and conditions of the Offers, to the extent required to meet further investor demand.

 

The deadline for receipt of applications for the Offers is 12.00 noon on 4 April 2022 in relation to the tax year 2021/22 and 12.00 noon on 27 May 2022 in relation to the tax year 2022/23. The Offers will close on 3 June 2022 unless a relevant Offer is fully subscribed by an earlier date or extended by the Board to no later than 9 September 2022.

 

As announced on 10 January 2022, the deadline by which Applications must be received and accepted to be eligible for the Early Investment Incentive discount under the Offers has been extended until close of business on Wednesday 2 February 2022. It is anticipated that the Companies will make initial allotments of new Ordinary Shares under their respective Offers as soon as practicable after that date.

 

Downloadable versions of the Prospectus documents are available at: www.mavencp.com/vctoffer.

 

Any enquiries in respect of the Offers, or requests for copies of the Prospectus documents (available free of charge), should be directed to:

 

Maven Capital Partners UK LLP

Kintyre House

205 West George Street

Glasgow

G2 2LW

 

Telephone: 0141 306 7400

E-mail: enquiries@mavencp.com

Maven Capital Partners UK LLPSecretary

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRFLFFRLFILVIF
Date   Source Headline
2nd Jul 20264:55 pmRNSTransaction in Own Shares
26th Jun 202610:39 amRNSUnaudited Net Asset Value and Interim Dividend
20th May 202610:00 amRNSAdmission of Further Securities to Trading
15th May 202610:05 amRNSIssue of Equity - Dividend Investment Scheme
12th May 20263:35 pmRNSUnaudited NAV - Dividend Investment Scheme
8th May 20267:00 amRNSTransaction in Own Shares
30th Apr 20261:30 pmRNSResult of AGM
30th Apr 202610:54 amRNSAdmission of Further Securities to Trading
29th Apr 202612:28 pmRNSIssue of Equity
20th Apr 202612:23 pmRNSPublication of a Supplementary Prospectus
15th Apr 202611:19 amRNSAdmission of Further Securities to Trading
14th Apr 202611:07 amRNSIssue of Equity
8th Apr 20269:28 amRNSAdmission of Further Securities to Trading
25th Mar 202610:54 amRNSAdmission of Further Securities to Trading
24th Mar 20265:32 pmRNSAnnual Financial Report
24th Mar 202612:11 pmRNSIssue of Equity
17th Mar 20264:36 pmRNSNet Asset Value(s)
27th Feb 20265:01 pmRNSTransaction in Own Shares
27th Feb 20267:00 amRNSUnaudited NAV and Dividend Declaration
18th Feb 20264:52 pmRNSAdmission of Further Securities to Trading
17th Feb 202611:05 amRNSDirector/PDMR Shareholding
17th Feb 202611:02 amRNSDirector/PDMR Shareholding
17th Feb 202611:02 amRNSDirector/PDMR Shareholding
17th Feb 202611:00 amRNSDirector/PDMR Shareholding
17th Feb 202610:55 amRNSIssue of Equity
4th Feb 20267:00 amRNSStatement re Offer for Subscription
21st Jan 202611:03 amRNSAdmission of Further Securities to Trading
16th Jan 20269:42 amRNSIssue of Equity
14th Jan 20262:35 pmRNSUnaudited NAV - Dividend Investment Scheme
16th Dec 202510:20 amRNSIssue of Equity
4th Dec 202510:35 amRNSUnaudited NAV and Second Interim Dividend
13th Nov 20254:47 pmRNSResult of General Meeting
28th Oct 20254:24 pmRNSTransaction in Own Shares
2nd Oct 20254:42 pmRNSPublication of a Prospectus
15th Sep 20251:08 pmRNSNet Asset Value(s)
29th Aug 20257:00 amRNSIssue of Equity
20th Aug 20252:13 pmRNSStatement re Dividend Investment Scheme
23rd Jul 20254:30 pmRNSHalf-year Report
22nd Jul 20254:49 pmRNSTransaction in Own Shares
16th Jul 20257:08 amRNSStatement re Offer for Subscription
10th Jul 20254:46 pmRNSStatement re Unaudited NAV and Interim Dividend
15th May 20253:57 pmRNSTransaction in Own Shares
9th May 20259:54 amRNSDirector/PDMR Shareholding
9th May 20259:51 amRNSIssue of Equity
6th May 202511:53 amRNSIssue of Equity
2nd May 20251:11 pmRNSAudited NAV - Dividend Investment Scheme
1st May 20253:15 pmRNSResult of AGM
17th Apr 202512:56 pmRNSPublication of Suppl.Prospcts
7th Apr 20257:00 amRNSIssue of Equity - Replacement
4th Apr 20256:17 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.